Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $5.38, down 0.09% on the session, giving a market capitalisation of $242.8M. On trailing twelve-month figures it carries a trailing P/E of 4.94, a net margin of 0.0%. Its beta of 2.13 implies it has historically moved more than the broad market.
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.
Third Harmonic Bio, Inc. is most often compared with the following Healthcare names: